References
1. Khashkhusha TR, Chan JSK, Harky A. ACE inhibitors and COVID-19: We don’t know yet. J Card Surg. 2020. http://doi.org/10.1111/jocs.14582
2. Cure E, Cumhur Cure M. Comment on ”Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade”. Nephron. 2020. http://doi.org/10.1159/000507786
3. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659. http://doi.org/10.1056/NEJMsr2005760
4. Paz Ocaranza M, Riquelme JA, García L, et al. Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2020;17(2):116-129. http://doi.org/ 10.1038/s41569-019-0244-8
5. Busse LW, Chow JH, McCurdy MT, Khanna AK. COVID-19 and the RAAS-a potential role for angiotensin II? Crit Care. 2020;24(1):136. http://doi.org/10.1186/s13054-020-02862-1
6. Chester AH, Borland JA. Chymase-dependent angiotensin II formation in human blood vessels. J Hum Hypertens. 2000;14(6):373-376.